NDAINTRAVENOUSPOWDER
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TECHNETIUM TC 99M MERTIATIDE KIT (technetium tc 99m mertiatide) by Jubilant Therapeutics is imaging, technetium tc 99m mertiatide is rapidly cleared from the blood. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Technetium Tc 99m Mertiatide is a radiopharmaceutical imaging agent administered intravenously as a reconstituted powder kit. It is rapidly cleared from the blood and excreted by the kidneys in the urine, enabling renal and urinary tract imaging. This diagnostic agent facilitates visualization of kidney function and structure in clinical nuclear medicine procedures.
Peak
Recent 2023 approval positions this product in growth-to-peak phase with moderate competitive intensity (30% pressure), indicating established but not dominant market positioning.
Mechanism of Action
imaging, Technetium Tc 99m Mertiatide is rapidly cleared from the blood. It is cleared by the kidneys and excreted in the urine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Technetium Tc 99m Mertiatide positions you in the niche but stable diagnostic imaging sector, with emphasis on clinical adoption, provider relationships, and payer negotiations rather than patient-facing marketing. Career progression depends on building nuclear medicine expertise and establishing market leadership in a focused therapeutic area.
Diagnostic Product ManagerMedical Science Liaison (Nuclear Medicine)
Worked on TECHNETIUM TC 99M MERTIATIDE KIT at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.